84. サルコイドーシス
［臨床試験数：143，薬物数：221（DrugBank：79），標的遺伝子数：82，標的パスウェイ数：165］
Searched query = "Sarcoidosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2009-010714-30-NL (EUCTR) | 22/12/2009 | 03/02/2011 | A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sarcoidosis - | Chronic sarcoidosis MedDRA version: 9.1;Level: LLT;Classification code 10039486;Term: Sarcoidosis | Product Name: Golimumab Liquid in prefilled syringe Product Code: CNTO 148 INN or Proposed INN: golimumab Other descriptive name: human anti TNF-alpha monoclonal antibody Product Name: ustekinumab liquid in prefilled syringe Product Code: CNTO1275 INN or Proposed INN: ustekinumab Other descriptive name: human anti-IL 12/23 monoclonal antibody | Centocor BV | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 2 | United Kingdom;Germany;Netherlands;Denmark;Belgium;France;Italy | |||
| 2 | EUCTR2009-010714-30-FR (EUCTR) | 10/11/2009 | 15/10/2009 | A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sarcoidosis - | Chronic sarcoidosis MedDRA version: 9.1;Level: LLT;Classification code 10039486;Term: Sarcoidosis | Product Name: Golimumab Liquid in prefilled syringe Product Code: CNTO 148 INN or Proposed INN: golimumab Other descriptive name: human anti TNF-alpha monoclonal antibody Product Name: ustekinumab liquid in prefilled syringe Product Code: CNTO1275 INN or Proposed INN: ustekinumab Other descriptive name: human anti-IL 12/23 monoclonal antibody | Centocor BV | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 180 | Phase 2 | United Kingdom;Germany;Netherlands;Denmark;Belgium;France;Italy | |||
| 3 | EUCTR2009-010714-30-DE (EUCTR) | 23/10/2009 | 08/07/2009 | A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sarcoidosis | A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sarcoidosis | Chronic sarcoidosis MedDRA version: 9.1;Level: LLT;Classification code 10039486;Term: Sarcoidosis | Product Name: Golimumab Liquid in prefilled syringe Product Code: CNTO 148 INN or Proposed INN: golimumab Other descriptive name: human anti TNF-alpha monoclonal antibody Product Name: ustekinumab liquid in prefilled syringe Product Code: CNTO1275 INN or Proposed INN: ustekinumab Other descriptive name: human anti-IL 12/23 monoclonal antibody | Janssen Biologics B.V. | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 2 | France;Belgium;Denmark;Netherlands;Germany;Italy;United Kingdom | ||
| 4 | EUCTR2009-010714-30-DK (EUCTR) | 12/10/2009 | 17/08/2009 | A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients with Sarcoidosis | A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sarcoidosis | Chronic sarcoidosis MedDRA version: 14.0;Level: PT;Classification code 10039486;Term: Sarcoidosis;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] | Product Name: Golimumab Liquid in prefilled syringe Product Code: CNTO 148 INN or Proposed INN: golimumab Other descriptive name: human anti TNF-alpha monoclonal antibody Product Name: ustekinumab liquid in prefilled syringe Product Code: CNTO1275 INN or Proposed INN: ustekinumab Other descriptive name: human anti-IL 12/23 monoclonal antibody | Janssen Biologics B.V. | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 2 | France;United States;Belgium;Romania;Denmark;Netherlands;Germany;Italy;United Kingdom | ||
| 5 | EUCTR2009-010714-30-BE (EUCTR) | 28/09/2009 | 08/07/2009 | A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients with Sarcoidosis | A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sarcoidosis | Chronic sarcoidosis MedDRA version: 13.1;Level: PT;Classification code 10039486;Term: Sarcoidosis;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Golimumab Liquid in prefilled syringe Product Code: CNTO 148 INN or Proposed INN: golimumab Other descriptive name: Human anti TNF-alpha monoclonal antibody Product Name: ustekinumab liquid in prefilled syringe Product Code: CNTO1275 INN or Proposed INN: ustekinumab Other descriptive name: Human anti-IL 12/23 monoclonal antibody | Janssen Biologics B.V. | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 2 | France;United States;Belgium;Denmark;Germany;Norway;Netherlands;Italy;United Kingdom |